KR101799264B1 - 골관절염 치료 - Google Patents

골관절염 치료 Download PDF

Info

Publication number
KR101799264B1
KR101799264B1 KR1020117017015A KR20117017015A KR101799264B1 KR 101799264 B1 KR101799264 B1 KR 101799264B1 KR 1020117017015 A KR1020117017015 A KR 1020117017015A KR 20117017015 A KR20117017015 A KR 20117017015A KR 101799264 B1 KR101799264 B1 KR 101799264B1
Authority
KR
South Korea
Prior art keywords
ser
csf
gly
leu
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117017015A
Other languages
English (en)
Korean (ko)
Other versions
KR20110128273A (ko
Inventor
죤 알랜 해밀튼
앤드류 데이빗 쿡
Original Assignee
더 유니버시티 오브 멜버른
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101799264(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 유니버시티 오브 멜버른 filed Critical 더 유니버시티 오브 멜버른
Publication of KR20110128273A publication Critical patent/KR20110128273A/ko
Application granted granted Critical
Publication of KR101799264B1 publication Critical patent/KR101799264B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020117017015A 2008-12-22 2009-12-21 골관절염 치료 Active KR101799264B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US61/139,679 2008-12-22
US16448609P 2009-03-30 2009-03-30
US61/164,486 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032850A Division KR101898982B1 (ko) 2008-12-22 2009-12-21 골관절염 치료

Publications (2)

Publication Number Publication Date
KR20110128273A KR20110128273A (ko) 2011-11-29
KR101799264B1 true KR101799264B1 (ko) 2017-11-20

Family

ID=42286786

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117017015A Active KR101799264B1 (ko) 2008-12-22 2009-12-21 골관절염 치료
KR1020177032850A Expired - Fee Related KR101898982B1 (ko) 2008-12-22 2009-12-21 골관절염 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177032850A Expired - Fee Related KR101898982B1 (ko) 2008-12-22 2009-12-21 골관절염 치료

Country Status (19)

Country Link
US (4) US9243061B2 (enExample)
EP (2) EP2376121B2 (enExample)
JP (3) JP5727379B2 (enExample)
KR (2) KR101799264B1 (enExample)
CN (2) CN106397591A (enExample)
AU (1) AU2009329814B2 (enExample)
BR (1) BRPI0918356B1 (enExample)
CA (1) CA2746827C (enExample)
CY (1) CY1117698T1 (enExample)
DK (1) DK2376121T4 (enExample)
ES (2) ES2572368T5 (enExample)
HK (1) HK1226938A1 (enExample)
HR (1) HRP20160577T4 (enExample)
HU (1) HUE028615T2 (enExample)
PL (1) PL2376121T5 (enExample)
RU (2) RU2712273C2 (enExample)
SI (2) SI2376121T1 (enExample)
SM (1) SMT201600156B (enExample)
WO (1) WO2010071924A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023412A2 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ234479A (en) 1989-07-14 1992-03-26 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
DK0486572T3 (da) 1989-08-11 1998-05-04 Amrad Corp Ltd Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
CA2555688C (en) † 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
KR101481844B1 (ko) * 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
MX2010010503A (es) † 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
EP3381471B1 (en) † 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023412A2 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies

Also Published As

Publication number Publication date
JP5727379B2 (ja) 2015-06-03
KR101898982B1 (ko) 2018-09-14
WO2010071924A1 (en) 2010-07-01
CN102271705A (zh) 2011-12-07
HK1226938A1 (en) 2017-10-13
DK2376121T3 (en) 2016-05-30
EP3056217A1 (en) 2016-08-17
ES2572368T5 (es) 2021-12-16
EP2376121B1 (en) 2016-03-09
EP2376121A1 (en) 2011-10-19
JP2015143233A (ja) 2015-08-06
JP6458086B2 (ja) 2019-01-23
JP2017200933A (ja) 2017-11-09
JP2012512815A (ja) 2012-06-07
US20200247895A1 (en) 2020-08-06
RU2712273C2 (ru) 2020-01-28
BRPI0918356A2 (pt) 2020-10-06
CY1117698T1 (el) 2017-05-17
RU2016102339A (ru) 2018-11-21
SMT201600156B (it) 2016-08-31
BRPI0918356B1 (pt) 2022-03-08
KR20110128273A (ko) 2011-11-29
AU2009329814B2 (en) 2015-06-18
PL2376121T5 (pl) 2021-09-27
SI2376121T1 (sl) 2016-07-29
ES2572368T3 (es) 2016-05-31
US9243061B2 (en) 2016-01-26
CA2746827A1 (en) 2010-07-01
US20120003234A1 (en) 2012-01-05
US20180066062A1 (en) 2018-03-08
EP2376121B2 (en) 2021-06-09
PL2376121T3 (pl) 2016-12-30
EP2376121A4 (en) 2013-04-03
US20160185868A1 (en) 2016-06-30
CA2746827C (en) 2018-01-23
KR20170128630A (ko) 2017-11-22
AU2009329814A1 (en) 2010-07-01
HRP20160577T1 (hr) 2016-07-29
RU2011127334A (ru) 2013-01-27
HRP20160577T4 (hr) 2021-08-20
SI2376121T2 (sl) 2021-11-30
ES2886063T3 (es) 2021-12-16
CN106397591A (zh) 2017-02-15
HUE028615T2 (en) 2016-12-28
EP3056217B1 (en) 2021-06-30
RU2016102339A3 (enExample) 2019-07-29
DK2376121T4 (da) 2021-08-16

Similar Documents

Publication Publication Date Title
KR101761324B1 (ko) 통증 치료
US20200247895A1 (en) Osteoarthritis treatment
KR20150064250A (ko) 신규 항-ｉｌ１３ 항체 및 그 용도
AU2015224416B2 (en) Osteoarthritis treatment
HK1162336A (zh) 骨关节炎治疗
HK1162335A (en) Pain treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110720

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160929

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170313

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170904

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171113

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171114

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20211026

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20211026

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20221025

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20221025

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20231023

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 8

End annual number: 8